Antiepileptic drug can now be used in pediatric patients
FDA has expanded the indication for topiramate (Qudexy XR, Upsher-Smith Laboratories) extended-release capsules within the pediatric population.
FDA has expanded the indication for topiramate (Qudexy XR, Upsher-Smith Laboratories) extended-release capsules within the pediatric population.
Qudexy XR, a once-daily, broad-spectrum antiepileptic drug, was previously approved for use as initial monotherapy in patients aged 10 years and older with partial-onset seizures (POS) or primary generalized tonic-clonic seizures. With this approval, it now offers prescribers an additional first-line treatment option in patients aged 2 years and older who are experiencing these seizures.
Related:Pediatric migraine drug gets FDA green light
The ability to sprinkle the drug onto soft food makes it a useful option for young children who may have difficulty swallowing whole capsules or tablets.
Related:FDA approves drug to treat rare bile acid synthesis disorders in kids, adults
It is also approved as an adjunctive therapy in patients aged 2 years or older with POS, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome.
Qudexy XR has been available in the United States since June 2014.
Read next:FDA approves DTaP-IPV combo vaccine for children ages 4 to 6
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More
